ST易联众(300096) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was ¥136,296,251.75, representing an increase of 88.20% compared to ¥72,422,850.80 in the same period last year[3]. - The net loss attributable to shareholders was ¥43,683,967.28, a 37.08% improvement from a loss of ¥69,430,631.97 in Q1 2022[3]. - The total income from sales of goods and services received was ¥158,719,772.50, a 52.08% increase from ¥104,369,194.91 in the same period last year[12]. - In Q1 2023, the company reported a net loss of ¥51,039,837.94, compared to a net loss of ¥92,100,064.17 in Q1 2022, representing a 44.6% improvement year-over-year[30]. - Total operating revenue for Q1 2023 was ¥79,296,397.89, up from ¥42,107,877.28 in Q1 2022, indicating an increase of 88.1%[29]. - The company's operating profit (loss) for Q1 2023 was -¥51,583,742.51, an improvement from -¥98,048,554.64 in the same period last year[29]. - The company recorded a total comprehensive loss of ¥34,321,328.31 in Q1 2023, compared to a loss of ¥122,287,694.30 in Q1 2022, reflecting a significant reduction of 72%[30]. Cash Flow and Assets - The net cash flow from operating activities improved to -¥75,344,658.27, a 58.51% reduction in loss compared to -¥181,576,490.07 in the previous year[3]. - The company's cash and cash equivalents decreased to CNY 64,334,651.49 from CNY 191,293,428.83 at the beginning of the year, reflecting a decline of approximately 66.4%[24]. - The company's cash and cash equivalents at the end of Q1 2023 were ¥50,708,789.13, down from ¥124,212,393.88 at the end of Q1 2022[34]. - Cash flow from operating activities showed a net outflow of ¥75,344,658.27 in Q1 2023, an improvement from a net outflow of ¥181,576,490.07 in Q1 2022[33]. - The total assets decreased by 7.04% to ¥1,281,940,812.49 from ¥1,379,003,291.77 at the end of the previous year[3]. - The total liabilities decreased to CNY 920,772,966.09 from CNY 983,514,117.06, reflecting a decrease of approximately 6.4%[26]. - The company's equity attributable to shareholders decreased to CNY 275,577,469.06 from CNY 302,542,926.71, a decline of about 8.9%[26]. Expenses and Investments - The company reported a significant increase in development expenditures, rising by 42.00% to ¥1,824,380.41 due to increased R&D investments[8]. - The total operating costs for the first quarter of 2023 amounted to CNY 184,329,378.35, compared to CNY 177,246,252.87 in the previous year, indicating a year-over-year increase of about 4.1%[28]. - Research and development expenses decreased to ¥27,159,324.46 in Q1 2023 from ¥50,425,959.72 in Q1 2022, a reduction of 46.1%[29]. - The company experienced a 60.12% decrease in tax refunds received, amounting to ¥3,427,147.97 compared to ¥8,593,745.46 in Q1 2022[12]. - The company reported a significant increase in sales expenses, which decreased by 33.15% to ¥19,630,063.80, attributed to personnel structure optimization[11]. Shareholder Information - As of March 31, 2023, the total number of ordinary shareholders was 31,609, with no preferred shareholders[15]. - Zhang Xi holds 16.21% of the shares, amounting to 69,681,649 shares, with 52,261,237 shares frozen[15]. - Micro Medical Holdings Limited reduced its stake by 11,500,600 shares, representing 2.67% of the total share capital, between December 23, 2022, and February 2, 2023[20]. - The company has no known related party relationships among the top shareholders[16]. - The company did not report any changes in the number of restricted shares during the period[19]. Other Financial Activities - The company transferred 13.5% of its stake in Haibao Life Insurance Co., Ltd. for CNY 260 million, retaining a 6.5% stake post-transaction[21]. - The company completed mortgage procedures with Industrial Bank Co., Ltd. for a comprehensive credit limit application[20]. - The total cash inflow from financing activities in Q1 2023 was ¥42,015,097.85, compared to ¥155,052,500.00 in Q1 2022, indicating a decrease of 72.9%[34]. - The company reported other comprehensive income of ¥16,718,509.63 in Q1 2023, contrasting with a loss of -¥30,187,630.13 in Q1 2022[30].